INmune Bio Stock Surges on Positive Alzheimer's Trial Data

INmune Bio, a clinical-stage biotechnology company, has announced that it will hold a conference call on June 30 at 8:00 AM Eastern Time to disclose preliminary data from its MINDFuL Phase 2 trial of the candidate drug XPro for the treatment of early Alzheimer's disease (AD). The market responded positively to this news, with the company's stock experiencing significant gains.

XPro is a tumor necrosis factor (TNF) inhibitor, distinct from other TNF inhibitors currently available. Unlike other TNF inhibitors, XPro specifically neutralizes soluble TNF without affecting transmembrane TNF or TNF receptors. This targeted approach aims to reduce neuroinflammation in diseases such as Alzheimer's, potentially offering a new therapeutic option for patients suffering from this debilitating condition.

The MINDFuL trial has enrolled 208 patients diagnosed with mild cognitive impairment (MCI) or mild AD, with an average age of 72. The primary endpoint of the trial is the change in cognitive scores relative to baseline, measured using the Early and Mild Alzheimer's Cognitive Composite (EMACC). The EMACC is a tool designed to objectively measure outcomes in early AD clinical trials. The trial's focus on early-stage Alzheimer's disease is particularly noteworthy, as effective treatments for this stage of the disease are currently limited.

The upcoming disclosure of preliminary data from the MINDFuL trial is anticipated to provide valuable insights into the efficacy and safety of XPro in treating early-stage Alzheimer's disease. This development is significant as it could potentially offer a new therapeutic option for patients suffering from this debilitating condition. The positive market reaction to the announcement reflects the high level of interest and hope surrounding the potential of XPro in addressing the unmet medical needs in Alzheimer's treatment.